Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
Gynecologic Cancer Trials
A Phase 1, Open Label, Dose Escalation and Cohort Expansion First in Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti LAG 3 mAb) Administered Alone or in Combination with REGN2810 (anti PD 1 mAb) in Patients with Advanced Malignancies
To evaluate safety and PK in order to determine an RP2D of REGN3767 as monotherapy and in combination with REGN2810 in patients with advanced malignancies, including lymphoma.
To assess preliminary anti-tumor activity of REGN3767 alone and in combination with REGN2810 (separately by cohort) as measured by ORR.
Molecular Analysis for Therapy Choice (MATCH)
This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for whom no standard treatment exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.
A Phase 1/2 Dose Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
This is a multicenter, Phase 1a/1b, study consisting of 2 parts, with Part 1 the Phase 1a portion of the study and Part 2 the Phase 1b portion. The aim of the study is to evaluate the safety and tolerability, as well as to obtain preliminary evidence of antitumor activity and anti-CACS activity, of NGM120 monotherapy in subjects with select advanced solid tumors (Part 1) and of NGM120 in combination with gemcitabine and Abraxane for the management of metastatic pancreatic cancer (Part 2). Part 2 will start at the same time as Part 1 and run concurrently.
A Phase III Randomized, Placebo Controlled Study of Pembrolizumab (MK 3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin, works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.
First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.